ZVRA — Zevra Therapeutics Share News
0.000.00%
Last trade - 00:00- $613.43m
- $391.86m
- $106.47m
Brief: Zevra Submits EU Application for Arimoclomol to Treat Niemann-Pick Disease Type C
U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial
U.S. STOCKS ON THE MOVE-Tesla, ABM Industries, Regeneron
U.S. STOCKS ON THE MOVE-Zevra Therapeutics, Abeona Therapeutics, Greenbrier
Zevra Therapeutics rises after H.C. Wainwright starts coverage with 'buy' rating
Prices for new US drugs doubled in 4 years as focus on rare disease grows
Brief: Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees
Zevra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Zevra Therapeutics Q1 Operating Expenses USD 22.803 Million
Zevra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Zevra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Zevra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher
Brief: Zevra Therapeutics Files Preliminary Proxy
Zevra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Zevra Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Zevra Therapeutics, Agilent Technologies
Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln
Brief: Zevra Therapeutics Announces Organizational Changes